Blood pressure control 1 year after referral to a hypertension specialist

Journal of Clinical Hypertension

Volumn 15, Issue 9, 2013, Pages 624-629

  Denker, Matthew G ^a   Haddad, Danny B ^a   Townsend, Raymond R ^a   Cohen, Debbie L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE; ALDOSTERONE ANTAGONIST; CREATININE; DIURETIC AGENT; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; VASODILATOR AGENT;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE REGULATION; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEDICAL RECORD REVIEW; MEDICAL SPECIALIST; PATIENT REFERRAL; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL;

ADULT; AGED; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; REFERRAL AND CONSULTATION; RENIN; RETROSPECTIVE STUDIES; SPECIALIZATION; TREATMENT OUTCOME;

EID: 84883459093     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12146     Document Type: Article

References (18)

1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
2. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294:466-472.
3. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-1080.
4. Townsend RR. Attending rounds: a patient with drug-resistant hypertension. Clin J Am Soc Nephrol. 2011;6:2301-2306.
5. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.
6. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
7. Blumenfeld JD, Laragh JH. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens. 1998;11:894-896.
8. Egan BM, Basile JN, Rehman SU, et al. Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22:792-801.
9. Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med. 1973;55:261-274.
10. Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892-896.
11. Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:2217-2226.
12. Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039-1045.
13. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002;970:89-100.
14. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80-85.
15. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898-902.
16. Tiu SC, Choi CH, Shek CC, et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab. 2005;90:72-78.
17. Stowasser M, Gordon RD. Aldosterone assays: an urgent need for improvement. Clin Chem. 2006;52:1640-1642.
18. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-3281.